Navigation Links
The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future
Date:4/24/2008

st ionizing Radiation, as well as, other items.

The Quigley Corporation makes no representation that the US Food and Drug Administration or any other regulatory agency will allow this Investigational New Drug to be marketed. Furthermore, no claim is made that potential medicine discussed herein is safe, effective, or approved by the Food and Drug Administration.

Additionally, data that demonstrates activity or effectiveness in animals or in vitro tests do not necessarily mean the formula test compound; referenced herein will be effective in humans. Safety and effectiveness in humans will have to be demonstrated by means of adequate and well-controlled clinical studies before the clinical significance of the formula test compound is known. Readers should carefully review the risk factors described in filings the Company files from time to time with the Securities and Exchange Commission.

About The Quigley Corporation

The Quigley Corporation (NASDAQ: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD-EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities and Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

C
'/>"/>

SOURCE The Quigley Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. The Quigley Corporation Reports Fourth Quarter & 2007 Annual Results; Increases Investment to $6.5 million in Pharmaceutical R&D in 2007
2. The Quigley Corporation Announces Sale of Its Health and Wellness Segment
3. STERIS Corporation Declares Regular Quarterly Dividend
4. Webcast Alert: Heska Corporations Annual Meeting of Stockholders Webcast
5. Vystar Corporation and Revertex Malaysia Sign Vytex(TM) NRL Production Contract
6. LifeSync Corporation Agrees to Sublicense Patent Portfolio to Triage Wireless
7. Shareholder Class Action Filed Against Candela Corporation by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. United American Healthcare Corporation Provides Update on TennCare RFP Awards
9. Select Medical Corporation Makes Historic Multi-Million Dollar Gift to Harrisburg University
10. United Nations Environment Programme and Bayer Corporation Announce North American Winners of International Childrens Painting Competition
11. Triple-S Management Corporation Schedules First-Quarter Earnings Release and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... (PRWEB) February 28, 2015 The ... is offering a new special. Throughout all of ... , This service can help ... problems and pain. Patients may notice certain symptoms that ... relining. These symptoms include: , 1.    Pain, clicking, and ...
(Date:2/28/2015)... Vancouver, BC (PRWEB) February 28, 2015 ... has recently announced that they now provide business consulting ... services, such as corporate tax planning and succession planning. ... be entrusted to experienced professionals. On top of this, ... difficult to handle corporate accounting. As a result, Mew ...
(Date:2/28/2015)... 2015 Indosoft Inc , developers ... Asterisk, are pleased to announce the development of Q-Suite ... 5.8 versions of Q-Suite, this new version will include ... of new features to the leading edge call center ... 5.9 will add features to enhance security and protection. ...
(Date:2/28/2015)... For those people who are unable to attend ... Research Foundation (Meso Foundation) will broadcast its Symposium ... 9:30 AM. , The live broadcast is free of ... accessed through any browser on a computer or smartphone/device ... a unique event that covers important treatment information and ...
(Date:2/28/2015)... 2015 Pioneer Millworks reclaimed USA wood ... & Construction Materials Show, an annual, premier sustainable building ... suppliers and top manufacturers of the latest building products, ... sourced and manufactured by Pioneer Millworks from their ... Japan at restaurants, hotels, retailers, and corporate offices. ...
Breaking Medicine News(10 mins):Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:Mesothelioma Cancer Research Foundation Broadcasting Symposium Live 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2
... - When administered before chemoradiation, the common anti-cancer drug ... of colostomies needed when compared to the standard treatment ... study published in the April 23 issue of the ... the largest cooperative phase III randomized controlled trial of ...
... Experimental use of cisplatin no better than standard treatment, ... -- Compared to the standard treatment regimen for anal ... before other treatments didn,t improve disease-free survival and resulted ... U.S. study. , Currently, the preferred primary therapy for ...
... SAN JOSE, Calif., April 22 VNUS(R) Medical,Technologies, ... of medical devices,for the minimally invasive treatment of ... teleconference and webcast,held yesterday at 2:00 p.m. PT/5:00 ... the Question-and-Answer period did not,take place as planned., ...
... (NYSE: PER ) and Surgical Care Affiliates ... will implement advanced technology,solutions to serve as a ... will help SCA improve support for its more ... and surgical,hospitals across the country. Perot Systems, services ...
... 22 Honda Motor Co., Ltd. will showcase an,experimental ... walking,for the elderly and other people with weakened leg ... & Rehabilitation for,the Elderly & the Disabled (BARRIER FREE ... 25 through Sunday, April 27, 2008., (Photo: ...
... April 22, 2008 Help is on the way for ... suffer from chronic pain in their backs and legs, thanks ... specialists. , Called a hybrid technique, the procedure ... cord) stimulator with a newer technology known as peripheral nerve ...
Cached Medicine News:Health News:Study finds cisplatin less effective than standard treatment for patients with anal cancer 2Health News:New Anal Cancer Therapy Fails to Improve Outcomes 2Health News:Perot Systems and Surgical Care Affiliates Sign Five-Year Agreement to Implement Advanced Technology Solutions 2Health News:Perot Systems and Surgical Care Affiliates Sign Five-Year Agreement to Implement Advanced Technology Solutions 3Health News:Honda to Showcase Experimental Walking Assist Device 2Health News:Mix of 2 pain-relief procedures can end chronic back and leg pain without drugs 2Health News:Mix of 2 pain-relief procedures can end chronic back and leg pain without drugs 3
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. ... from a pre-clinical study published in the ... ( www.pnas.org/cgi/doi/10.1073/pnas.1500712112 ) that showed when ibrutinib (IMBRUVICA ... (a checkpoint inhibitor), suppression of tumor growth was ... when treating certain hematologic cancers and solid tumors ...
(Date:2/27/2015)... Pharmaceuticals, Inc. (Nasdaq: ISIS ) today announced ... loss (NOL) guidance and its cash guidance ending the ... financial results were due in large part to the ... from its partners.  Isis, pro forma NOL of $16.3 ... its 2013 NOL of $40.2 million. On a GAAP ...
(Date:2/27/2015)... 2015   Synageva BioPharma Corp. (Synageva) ... developing therapeutic products for rare diseases, joins the ... Organisation for Rare Diseases™ (EURORDIS™), The Global Genes ... Rare Disease Day. On the last ... and other participants conduct special events to raise ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... 2011 In the press release, "Lilly Presents Data ... 2011, by Eli Lilly and Company (NYSE: LLY ... overall responses were as follows:  one partial response in the ... disease of 41 percent (n=9) in leiomyosarcoma; 35 percent (n=6) ...
... Holdings, Inc., (NYSE: HRC ) invites you to ... Annual Health Care Conference in Los Angeles on June 8, ... to listen to the live discussion via the internet link ... http://cc.talkpoint.com/gold006/060711a_lr/?entity=37_TJC531W .  A recorded replay of the discussion will be ...
Cached Medicine Technology:Correction: Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcomas 2Correction: Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcomas 3Correction: Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcomas 4Correction: Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcomas 5Correction: Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcomas 6
... CycloPhotocoagulation (ECP) is a surgical approach to ... visualized laser application. The ciliary body (which ... surgeon, from the anterior or posterior segment, ... target tissues are easily and accurately identified ...
... CycloPhotocoagulation (ECP) is a surgical approach to ... visualized laser application. The ciliary body (which ... surgeon, from the anterior or posterior segment, ... target tissues are easily and accurately identified ...
... Craftsmanship have produced the finest ... Ocutek® now makes them available ... the coveted Meisterbrief certificate, which ... qualified to become Ocutek instrument ...
... Endoscopic CycloPhotocoagulation (ECP) is a surgical ... endoscopy and visualized laser application. The ciliary ... by the surgeon, from the anterior or ... time. The target tissues are easily and ...
Medicine Products: